A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 microg and 1200 microg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2011
At a glance
- Drugs AZD 3199; AZD 3199; Moxifloxacin
- Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Asthma; Bacterial infections; Chronic obstructive pulmonary disease; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
- Focus Pharmacodynamics
- 23 Oct 2010 New trial record